SARS-CoV-2’s ability to mimic MPO seems to provide a greater threat for triggering new-onset MS or worsening of MS symptoms in genetically predisposed patients, as seen during the COVID-19 pandemic [59,60]. Here, MPO is linked to myeloid sarcoma.